PD10 - PD10: Prostate Cancer: Advanced (including Drug Therapy) I

Podium Presenter(s)

• 

  Himanshu Arora, PhD,MSc,BS

  Assistant Professor
  University of Miami

  PDF Slides and Audio
• SC

  Simon Chowdhury, MD

  PDF Slides and Audio
• 

  Patrick Davey, MD

  Northampton General Hospital NHS Trust

  PDF Slides and Audio
• 

  Stephane DROUPY

  CHU de Nimes, Université de Montpellier

  PDF Slides and Audio
• 

  Mariaconsiglia Ferriero, MD,PhD

  Sapienza University of Rome, Italy

  PDF Slides and Audio
• JJ

  Jie Jin
• SK

  Sung Han Kim, MD
• DL

  Daniel Lee
• 

  Jui-Ming Liu, MD

  Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
• 

  Neal Shore, MD

  Carolina Urologic Research Center

  PDF Slides and Audio
• JS

  Joshua Sterling, MD

  Robert Wood Johnson Medical School

  PDF Slides and Audio
• 

  Hari Vigneswaran, MD

  University of Illinois at Chicago; Karolinska Institutet

  PDF Slides and Audio

Presentations:

• 7:00 AM – 9:00 AM

  PD10-01: Preclinical efficacy & mechanism of action of combination of nitric oxide donor and growth hormone-releasing hormone antagonists for castration-resistant prostate cancer
  Himanshu Arora, PhD,MSc,BS – University of Miami
• 7:00 AM – 9:00 AM

  PD10-02: The mTORC1/2 Dual Inhibitor AZD2014 with Potent Antitumor Activity in Docetaxel Sensitive/Resistant Prostate Cancer in Vitro.
  Jie Jin
• 7:00 AM – 9:00 AM

  PD10-03: A randomized control study of a prospective questionnaire analysis about the efficacy of smart health after-care including the physical muscle enforced function test in patients with advanced or metastatic prostate cancer who underwent an androgen deprivation test after primary curative therapy
  Sung Han Kim, MD
• 7:00 AM – 9:00 AM

  PD10-04: Impact of primary prostate cancer treatment with subsequent metastatic disease: Comparative analysis and survival outcomes in a real-world practice setting.
  Daniel Lee
• 7:00 AM – 9:00 AM

  PD10-05: Managing lines of therapy in castration resistant prostate cancer: real life snapshot from a multicenter cohort
  Mariaconsiglia Ferriero, MD,PhD – "Regina Elena" National Cancer Institute
• 7:00 AM – 9:00 AM

  PD10-06: Real-world Treatment Patterns in Patients with Castration-resistant Prostate Cancer
  Hari Vigneswaran, MD
• 7:00 AM – 9:00 AM

  PD10-07: Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy, subgroup analysis of EQUINOXE study
  Stephane DROUPY
• 7:00 AM – 9:00 AM

  PD10-08: Androgen Deprivation Therapy and the Risk of Dementia in 55,310 Patients with Prostate Cancer
  Jui-Ming Liu, MD
• 7:00 AM – 9:00 AM

  PD10-09: Interim analysis of phase 2 randomized prospective study on neoadjuvant apalutamide/abiraterone acetate with prednisone and the feasibility of performing nerve-sparing radical prostatectomy in men with high-risk prostate cancer (NCT02949284)
  Joshua Sterling, MD
• 7:00 AM – 9:00 AM

  PD10-10: Impact of baseline disease volume and prior docetaxel therapy on prostate-specific antigen-related outcomes in patients with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus androgen deprivation therapy
  Neal D. Shore, MD
• 7:00 AM – 9:00 AM

  PD10-11: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses
  Simon Chowdhury, MD – Sarah Cannon Research Institute, London, UK
• 7:00 AM – 9:00 AM

  PD10-12: Cardiovascular risk with GnRH agonists and antagonists: Real-world data from UK primary care
  Patrick Davey, MD